Making of a biotech hub in India

2 February 2022

India's national biotech development strategy has called for more engagement with start-ups and seeks to leverage the public-private partnership model to take the industry to $150 billion by 2025. As India prepares to capitalize on the altering nature of global value chains, different states have been made relevant stakeholders with the formation of new investment hotspots, reports The Pharma Letter’s India correspondent.

The country is gearing towards becoming a world recognized innovation and biomanufacturing hub and is looking for notable contributions from individual states. Though only 20 states and two union territories currently have a biotechnology policy in place, the government has said a strong investment-led growth in biotech output at a disaggregated level will play a critical role in boosting the overall biotech output in the country.

For India’s biotechnology industry, the period from 2015-2020 was one of immense growth, with the total industry value doubling from $35.2 billion to $70.2 billion in just five years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK